MIMEDX GROUP INC (MDXG) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:MDXG • US6024961012

5.11 USD
-0.03 (-0.58%)
At close: Jan 30, 2026
5.13 USD
+0.02 (+0.39%)
After Hours: 1/30/2026, 8:04:10 PM

MDXG Key Statistics, Chart & Performance

Key Statistics
Market Cap756.79M
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Shares148.10M
Float145.45M
52 Week High8.75
52 Week Low5.05
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)0.36
PE14.19
Fwd PE20.45
Earnings (Next)02-24
IPO2007-08-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
MDXG short term performance overview.The bars show the price performance of MDXG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

MDXG long term performance overview.The bars show the price performance of MDXG in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of MDXG is 5.11 USD. In the past month the price decreased by -24.52%. In the past year, price decreased by -41.26%.

MIMEDX GROUP INC / MDXG Daily stock chart

MDXG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MDXG Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to MDXG. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDXG Financial Highlights

Over the last trailing twelve months MDXG reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS decreased by -35.71% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.38%
ROA 12.8%
ROE 17.09%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%200%
Sales Q2Q%35.3%
EPS 1Y (TTM)-35.71%
Revenue 1Y (TTM)14.77%

MDXG Forecast & Estimates

11 analysts have analysed MDXG and the average price target is 12.44 USD. This implies a price increase of 143.52% is expected in the next year compared to the current price of 5.11.

For the next year, analysts expect an EPS growth of 47.72% and a revenue growth 18% for MDXG


Analysts
Analysts81.82
Price Target12.44 (143.44%)
EPS Next Y47.72%
Revenue Next Year18%

MDXG Ownership

Ownership
Inst Owners71.94%
Ins Owners1.79%
Short Float %3.7%
Short Ratio6.14

About MDXG

Company Profile

MDXG logo image MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 837 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.

Company Info

MIMEDX GROUP INC

1775 W Oak Commons Court, Ne

Marietta GEORGIA 30062 US

CEO: Timothy R. Wright

Employees: 837

MDXG Company Website

MDXG Investor Relations

Phone: 17706519100

MIMEDX GROUP INC / MDXG FAQ

Can you describe the business of MIMEDX GROUP INC?

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 837 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.


Can you provide the latest stock price for MIMEDX GROUP INC?

The current stock price of MDXG is 5.11 USD. The price decreased by -0.58% in the last trading session.


Does MDXG stock pay dividends?

MDXG does not pay a dividend.


What is the ChartMill technical and fundamental rating of MDXG stock?

MDXG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Is MIMEDX GROUP INC (MDXG) expected to grow?

The Revenue of MIMEDX GROUP INC (MDXG) is expected to grow by 18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for MIMEDX GROUP INC?

MIMEDX GROUP INC (MDXG) currently has 837 employees.